Mesenchymal Stem/Stromal Cell-Based Therapy for Heart Failure - What Is the Best Source?

摘要: Transplantation of stem/progenitor cells is a promising, emerging treatment for heart failure (HF) in the modern era. Mesenchymal stem/stromal (MSCs) are considered as one most promising cell sources this purpose, because their powerful secretion reparative factors and immunomodulatory ability. To date, various MSCs have been examined HF preclinical or clinical studies, including adult tissues (bone marrow adipose tissue), perinatal (umbilical cord amnion), pluripotent stem (induced embryonic cells). Adult tissue-derived more extensively examined. Previous trials suggested safety feasibility these treatment, but therapeutic effects remain arguable. Perinatal advantages removing necessity invasiveness biopsy mass production. An increasing number studies (albeit early stage) conducted. Pluripotent cell-derived may be another source mass-production ability underpinned by unlimited expansion with consistent quality. However, risk tumorigenicity restricts application. In review, we summarize current information available from highlighting disadvantages each MSC type. This will provide an insight into consideration best HF.